### Indication
- Hookworm diseases

### INN
- Mebendazole

### Medicine type
- Chemical agent

### List type
- Core

### Formulations
- Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)

### EML status history
- First added in 1977 ([TRS 615](https://www.who.int/prod/eng/trs/reports/trs615.pdf))
- Changed in 1979 ([TRS 641](https://www.who.int/prod/eng/trs/reports/trs641.pdf))
- Changed in 1982 ([TRS 685](https://www.who.int/prod/eng/trs/reports/trs685.pdf))
- Changed in 1987 ([TRS 770](https://www.who.int/prod/eng/trs/reports/trs770.pdf))
- Changed in 1995 ([TRS 867](https://www.who.int/prod/eng/trs/reports/trs867.pdf))
- Changed in 2007 ([TRS 950](https://www.who.int/prod/eng/trs/reports/trs950.pdf))
- Changed in 2011 ([TRS 965](https://www.who.int/prod/eng/trs/reports/trs965.pdf))

### Sex
- All

### Age
- Also recommended for children

### Therapeutic alternatives
- The recommendation is for this specific medicine

### Patent information
- Patents have expired in most jurisdictions
  - Read more about patents.

### Wikipedia
- [Mebendazole](https://en.wikipedia.org/wiki/Mebendazole)

### DrugBank
- [Mebendazole](https://www.drugbank.ca/drugs/DB00109)

---

**Summary of evidence and Expert Committee recommendations**

The Committee also decided to delete the square box symbol with mebendazole as all other relevant benzimidazoles are already included in the Model List as individual entries.